Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.

Abstract

OBJECTIVES:

To determine the prognostic impact of anemia in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).

BACKGROUND:

Whether the periprocedural use of bivalirudin as compared with UFH in anemic patients undergoing TAVR has an impact on outcomes remains unknown.

METHODS:

The BRAVO-3 trial compared the use of bivalirudin versus UFH in 802 high risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence (defined as hemoglobin levels <13 g/dl in men and <12 g/dl in women) or absence of anemia. The primary outcomes were net adverse cardiac events (NACE; a composite of all-cause mortality, myocardial infarction, stroke, or bleeding) and major bleeding (Bleeding Academic Research Consortium ≥3b) at 30 days.

RESULTS:

Among 798 patients with available baseline hemoglobin levels, 427 (54%) were anemic of whom 221 (52%) received bivalirudin. There were no significant differences in NACE and major bleeding at 30 days between patients with and without anemia, irrespective of the type of anticoagulant used (pinteraction  = 0.71 for NACE, pinteraction  = 1.0 for major bleeding). However, anemic patients had a higher risk of major vascular complications (adjusted OR 2.43, 95% CI 1.42-4.16, p = 0.001), and acute kidney injury (adjusted OR 1.74, 95% CI 1.16-2.59, p = 0.007) compared to non-anemic patients at 30 days.

CONCLUSIONS:

Anemia was not associated with a higher risk of NACE or major bleeding at 30 days after TAVR without modification of the treatment effects of periprocedural anticoagulation with bivalirudin versus UFH.

• Authors: Victor Razuk, Anton Camaj, Davide Cao, Johny Nicolas, Christian Hengstenberg, Samantha Sartori, Zhongjie Zhang, David Power, Frans Beerkens, Mauro Chiarito, Nicolas Meneveau, Christophe Tron, Nicolas Dumonteil, Julian D Widder, Markus Ferrari, Roberto Violini, Pieter R Stella, Raban Jeger, Prodromos Anthopoulos, Roxana Mehran, George D Dangas
• Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 98 Issue 6 Pg. E870-E880 (11 15 2021) ISSN: 1522-726X [Electronic] United States
• PMID: 33909348 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2021 Wiley Periodicals LLC.

Chemical References

• Antithrombins
• Nitriles
• Heparin
• tetrachloroisophthalonitrile

Topics

• Anemia (diagnosis)
• Antithrombins
• Aortic Valve Stenosis (diagnostic imaging, surgery)
• Female
• Heparin
• Humans
• Male
• Nitriles
• Transcatheter Aortic Valve Replacement (adverse effects)
• Treatment Outcome